Byrne Adam, Macdonald D Blair, Kirkpatrick Iain D C, Pham Magali, Green Courtney R, Copaescu Ana Maria, McInnes Matthew D F, Ling Ling, Ellis Anne, Costa Andreu F
Department of Pediatrics, Division of Infectious Disease, Immunology & Allergy, University of Ottawa, Ottawa, ON, Canada.
Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
Can Assoc Radiol J. 2025 Jan 11:8465371241311253. doi: 10.1177/08465371241311253.
Contrast media, including iodinated contrast media and gadolinium-based contrast agents, are commonly administered pharmaceuticals with excellent safety profiles. However, a minority of the population may experience a hypersensitivity reaction following intravenous administration. Hypersensitivity reactions can be immediate or delayed, and range from mild, such as urticaria, to severe, including anaphylaxis. There is emerging evidence that longstanding pretreatment protocols, such as diphenhydramine and corticosteroids, are ineffective and have the potential for side effects and other harms. Moreover, the evidence for efficacy on which this practice is based is weak and outdated. A joint collaborative working group of representatives from the Canadian Association of Radiologists and the Canadian Society of Allergy and Clinical Immunology was assembled to inform medical professionals and hospital policies regarding hypersensitivity reactions to contrast media. The objectives of the working group were to provide an overview of the epidemiology, physiology, risk factors, and types of hypersensitivity reactions; to synthesize the evidence for pretreatment strategies that minimize the risk of a breakthrough reaction for both iodinated contrast media and gadolinium-based contrast agents; to review the allergy investigations used to evaluate patients with a history of severe hypersensitivity reaction; and to provide an overview of existing guidelines. Following appraisal of the evidence, the working group established recommendations based on consensus in this practice guidance.
造影剂,包括碘化造影剂和钆基造影剂,是常用药物,具有良好的安全性。然而,少数人在静脉注射后可能会发生过敏反应。过敏反应可分为即刻反应或延迟反应,范围从轻度,如荨麻疹,到严重的,包括过敏反应。越来越多的证据表明,长期使用的预处理方案,如苯海拉明和皮质类固醇,是无效的,并且有可能产生副作用和其他危害。此外,这种做法所依据的疗效证据薄弱且过时。加拿大放射学家协会和加拿大过敏与临床免疫学会的代表组成了一个联合协作工作组,为医疗专业人员和医院制定关于造影剂过敏反应的政策提供信息。该工作组的目标是概述过敏反应的流行病学、生理学、风险因素和类型;综合有关预处理策略的证据,以尽量降低碘化造影剂和钆基造影剂发生突破性反应的风险;审查用于评估有严重过敏反应病史患者的过敏检查;并概述现有指南。在对证据进行评估后,工作组在本实践指南中根据共识制定了建议。